Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's D&A?
- Ligand Pharmaceuticals (LGND) reported D&A of $8.22M in Q2 2026.
- How has Ligand Pharmaceuticals's D&A changed year-over-year?
- Ligand Pharmaceuticals's D&A decreased by 3.6% year-over-year, from $8.52M to $8.22M.
- What is the long-term trend for Ligand Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's D&A has grown at a -9.8% compound annual growth rate (CAGR), from $51.07M to $33.78M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Ligand Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude